These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3849259)

  • 1. Three-year experience with amikacin sulfate as an exclusive surgical aminoglycoside in a large acute-care hospital.
    Lee JT
    Am J Med; 1985 Jul; 79(1A):37-42. PubMed ID: 3849259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aminoglycoside resistance in gram-negative bacilli during increased amikacin use. Comparison of experience in 14 United States hospitals with experience in the Minneapolis Veterans Administration Medical Center.
    Gerding DN; Larson TA
    Am J Med; 1985 Jul; 79(1A):1-7. PubMed ID: 4025364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control of emergence of multi-resistant gram-negative bacilli by exclusive use of amikacin.
    Ruiz-Palacios GM; Ponce de Leon S; Sifuentes J; Ponce de Leon S; Calva JJ; Huazano F; Ontiveros C; Ojeda F; Bobadilla M
    Am J Med; 1986 Jun; 80(6B):71-5. PubMed ID: 3089006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic resistance patterns during aminoglycoside restriction.
    Young EJ; Sewell CM; Koza MA; Clarridge JE
    Am J Med Sci; 1985 Dec; 290(6):223-7. PubMed ID: 3936358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and microbiologic consequences of amikacin use during a 42-month period.
    Berk SL; Alvarez S; Ortega G; Verghese A; Holtsclaw-Berk SA
    Arch Intern Med; 1986 Mar; 146(3):538-41. PubMed ID: 3954526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of aerobic gram-negative bacilli to aminoglycosides. Effects of 45 months of amikacin as first-line aminoglycoside therapy.
    Saavedra S; Vera D; Ramírez-Ronda CH
    Am J Med; 1986 Jun; 80(6B):65-70. PubMed ID: 3014877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital.
    Gerding DN; Larson TA; Hughes RA; Weiler M; Shanholtzer C; Peterson LR
    Antimicrob Agents Chemother; 1991 Jul; 35(7):1284-90. PubMed ID: 1929283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of amikacin in the management of intra-abdominal sepsis.
    Dougherty SH
    Am J Med; 1985 Jul; 79(1A):28-36. PubMed ID: 3895904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance surveillance programs and the incidence of gram-negative bacillary resistance to amikacin from 1967 to 1985.
    Gerding DN; Larson TA
    Am J Med; 1986 Jun; 80(6B):22-8. PubMed ID: 3089003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amikacin treatment of pulmonary infections involving gentamicin-resistant gram-negative bacilli.
    Bartlett JG
    Am J Med; 1977 Jun; 62(6):945-8. PubMed ID: 868911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five-year surveillance of aminoglycoside usage in a university hospital.
    Betts RF; Valenti WM; Chapman SW; Chonmaitree T; Mowrer G; Pincus P; Messner M; Robertson R
    Ann Intern Med; 1984 Feb; 100(2):219-22. PubMed ID: 6691664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replacement of gentamicin by amikacin as a means of decreasing gentamicin resistance of gram-negative rods in a neonatal intensive care unit.
    Wielunsky E; Drucker M; Cohen T; Reisner SH
    Isr J Med Sci; 1983 Nov; 19(11):1006-8. PubMed ID: 6662682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upper and lower urinary tract infections: amikacin's role in managing surgical complications.
    Childs SJ
    Am J Med; 1986 Jun; 80(6B):210-5. PubMed ID: 3728530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amikacin therapy of severe infections produced by gram-negative bacilli resistant to gentamicin.
    Valdivieso M; Bodey GP
    Am J Med Sci; 1977; 273(2):177-84. PubMed ID: 860733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of pediatric infections with amikacin as first-line aminoglycoside.
    Shulman ST; Yogev R
    Am J Med; 1985 Jul; 79(1A):43-50. PubMed ID: 4025367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amikacin therapy for severe gram-negative sepsis. Emphasis on infections with gentamicin-resistant organisms.
    Tally FP; Louie TJ; Weinstein WM; Bartlett JG; Gorbach SL
    Ann Intern Med; 1975 Oct; 83(4):484-8. PubMed ID: 1101761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of hospital-acquired urinary infections with amikacin (author's transl)].
    Weidner W; Nöske HD; Sziegoleit A; Schröder R; Leidenfrost U
    Med Klin; 1979 Jul; 74(27):1071-6. PubMed ID: 470792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The elimination of gentamicin-resistant gram-negative bacteria in a newborn intensive care unit.
    Raz R; Sharir R; Shmilowitz L; Kenes I; Ephros M
    Infection; 1987; 15(1):32-4. PubMed ID: 3646180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gentamicin-resistant bacillary infection. Clinical features and amikacin therapy.
    Leonard JM; McGee ZA; Alford RH
    Arch Intern Med; 1978 Feb; 138(2):201-5. PubMed ID: 415674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to aminoglycoside antibiotics of gram-negative bacilli isolated in Canadian hospitals.
    Duncan IB; Cheung EY; Haldane EV; Jackson FL; McNaughton RD; Morisset RA; Noble MA; Rennie RP; Ronald AR; Smith JA
    Can Med Assoc J; 1981 May; 124(9):1165-7. PubMed ID: 7237336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.